Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate

D. J. Chaplin, George Pettit, S. A. Hill

Research output: Contribution to journalArticle

291 Citations (Scopus)

Abstract

Combretastatin A4 phosphate has recently been identified by us as an agent which can selectively damage tumour neovasculature. In the current study we establish that combretastatin induces extensive blood flow shutdown in the tumour compared to normal tissues. Histological assessment of vascular shutdown shows that over 90% of vessels are rendered non-functional 6 hrs post-treatment with 100 mg/kg ip. Measurement of blood flow using a diffusible tracer 86RbCl indicates an overall reduction in perfusion by only 50-60%. This discrepancy probably reflects increased blood flow in the normal tissue vasculature supplying the tumour rim, which is caused by the ischaemia-induced release of vasoactive mediators. The vascular shutdown induced by administration of 100 mg/kg of combretastatin A4 phosphate results in extensive cell loss in the 24 hrs following treatment, however this is not translated into any significant effect on tumour growth. The continued growth of the tumour is attributed to an actively proliferating population of cells at the periphery of the tumour, which are dependent on normal tissue vasculature for their survival. We have attempted to target this residual population by combining combretastatin A4 phosphate with cytotoxic approaches. Cis platinum and radiation have been used. The results show that combretastatin can significantly enhance tumour response to both cis platinum and radiation. In summary, the studies confirm combretastatin A4 phosphate as a novel agent which targets and damages tumour vasculature and, moreover, indicate its potential therapeutic usefulness as an adjuvant to conventional cytotoxic approaches.

Original languageEnglish (US)
Pages (from-to)189-195
Number of pages7
JournalAnticancer Research
Volume19
Issue number1 A
StatePublished - 1999

Fingerprint

Blood Vessels
Neoplasms
Therapeutics
Cisplatin
Radiation
fosbretabulin
Health Services Needs and Demand
Growth
Ischemia
Perfusion
Population

Keywords

  • Cis Pt
  • Combretastatin a-4 phosphate
  • Radiation
  • Tumour blood vessels
  • Vascular targeting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anti-vascular approaches to solid tumour therapy : Evaluation of combretastatin A4 phosphate. / Chaplin, D. J.; Pettit, George; Hill, S. A.

In: Anticancer Research, Vol. 19, No. 1 A, 1999, p. 189-195.

Research output: Contribution to journalArticle

@article{a49f23af7c1d47afae5b38ee78c168da,
title = "Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate",
abstract = "Combretastatin A4 phosphate has recently been identified by us as an agent which can selectively damage tumour neovasculature. In the current study we establish that combretastatin induces extensive blood flow shutdown in the tumour compared to normal tissues. Histological assessment of vascular shutdown shows that over 90{\%} of vessels are rendered non-functional 6 hrs post-treatment with 100 mg/kg ip. Measurement of blood flow using a diffusible tracer 86RbCl indicates an overall reduction in perfusion by only 50-60{\%}. This discrepancy probably reflects increased blood flow in the normal tissue vasculature supplying the tumour rim, which is caused by the ischaemia-induced release of vasoactive mediators. The vascular shutdown induced by administration of 100 mg/kg of combretastatin A4 phosphate results in extensive cell loss in the 24 hrs following treatment, however this is not translated into any significant effect on tumour growth. The continued growth of the tumour is attributed to an actively proliferating population of cells at the periphery of the tumour, which are dependent on normal tissue vasculature for their survival. We have attempted to target this residual population by combining combretastatin A4 phosphate with cytotoxic approaches. Cis platinum and radiation have been used. The results show that combretastatin can significantly enhance tumour response to both cis platinum and radiation. In summary, the studies confirm combretastatin A4 phosphate as a novel agent which targets and damages tumour vasculature and, moreover, indicate its potential therapeutic usefulness as an adjuvant to conventional cytotoxic approaches.",
keywords = "Cis Pt, Combretastatin a-4 phosphate, Radiation, Tumour blood vessels, Vascular targeting",
author = "Chaplin, {D. J.} and George Pettit and Hill, {S. A.}",
year = "1999",
language = "English (US)",
volume = "19",
pages = "189--195",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - Anti-vascular approaches to solid tumour therapy

T2 - Evaluation of combretastatin A4 phosphate

AU - Chaplin, D. J.

AU - Pettit, George

AU - Hill, S. A.

PY - 1999

Y1 - 1999

N2 - Combretastatin A4 phosphate has recently been identified by us as an agent which can selectively damage tumour neovasculature. In the current study we establish that combretastatin induces extensive blood flow shutdown in the tumour compared to normal tissues. Histological assessment of vascular shutdown shows that over 90% of vessels are rendered non-functional 6 hrs post-treatment with 100 mg/kg ip. Measurement of blood flow using a diffusible tracer 86RbCl indicates an overall reduction in perfusion by only 50-60%. This discrepancy probably reflects increased blood flow in the normal tissue vasculature supplying the tumour rim, which is caused by the ischaemia-induced release of vasoactive mediators. The vascular shutdown induced by administration of 100 mg/kg of combretastatin A4 phosphate results in extensive cell loss in the 24 hrs following treatment, however this is not translated into any significant effect on tumour growth. The continued growth of the tumour is attributed to an actively proliferating population of cells at the periphery of the tumour, which are dependent on normal tissue vasculature for their survival. We have attempted to target this residual population by combining combretastatin A4 phosphate with cytotoxic approaches. Cis platinum and radiation have been used. The results show that combretastatin can significantly enhance tumour response to both cis platinum and radiation. In summary, the studies confirm combretastatin A4 phosphate as a novel agent which targets and damages tumour vasculature and, moreover, indicate its potential therapeutic usefulness as an adjuvant to conventional cytotoxic approaches.

AB - Combretastatin A4 phosphate has recently been identified by us as an agent which can selectively damage tumour neovasculature. In the current study we establish that combretastatin induces extensive blood flow shutdown in the tumour compared to normal tissues. Histological assessment of vascular shutdown shows that over 90% of vessels are rendered non-functional 6 hrs post-treatment with 100 mg/kg ip. Measurement of blood flow using a diffusible tracer 86RbCl indicates an overall reduction in perfusion by only 50-60%. This discrepancy probably reflects increased blood flow in the normal tissue vasculature supplying the tumour rim, which is caused by the ischaemia-induced release of vasoactive mediators. The vascular shutdown induced by administration of 100 mg/kg of combretastatin A4 phosphate results in extensive cell loss in the 24 hrs following treatment, however this is not translated into any significant effect on tumour growth. The continued growth of the tumour is attributed to an actively proliferating population of cells at the periphery of the tumour, which are dependent on normal tissue vasculature for their survival. We have attempted to target this residual population by combining combretastatin A4 phosphate with cytotoxic approaches. Cis platinum and radiation have been used. The results show that combretastatin can significantly enhance tumour response to both cis platinum and radiation. In summary, the studies confirm combretastatin A4 phosphate as a novel agent which targets and damages tumour vasculature and, moreover, indicate its potential therapeutic usefulness as an adjuvant to conventional cytotoxic approaches.

KW - Cis Pt

KW - Combretastatin a-4 phosphate

KW - Radiation

KW - Tumour blood vessels

KW - Vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=0032950870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032950870&partnerID=8YFLogxK

M3 - Article

C2 - 10226542

AN - SCOPUS:0032950870

VL - 19

SP - 189

EP - 195

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -